FINWIRES · TerminalLIVE
FINWIRES

EVTは2026年度のホテルEBITDAはわずかな成長にとどまると予測する一方、需要の低迷が懸念されると警告した。

By

-- EVT(ASX:EVT)は、2026年度のホテル事業における調整後EBITDA(金利・税金・減価償却費控除前利益)が前年比でわずかに増加すると予想している。これは、金曜日にオーストラリア証券取引所に提出された書類で明らかになった。 同社は、イースター休暇期間中に需要の低迷が見られ、特にニューサウスウェールズ州のスノーウィー・マウンテンズ地域など、車で行ける目的地に影響が出ていると指摘した。 一方、中東危機の影響は今のところ限定的であると同社は述べている。海外からのインバウンド客のキャンセルは、国内旅行客の減少とイベントによる国内需要によってほぼ相殺された。 しかし、海外からのインバウンド客、法人旅行、会議・イベントの今後の需要には軟化の兆候が見られ、予約リードタイムの短縮が見られると同社は付け加えた。 エンターテインメント事業については、ドイツのシネスターの好調な年初来業績に支えられ、2026年度は前年度比で「妥当な」成長が見込まれると同社は予測している。 しかしながら、ボンダイ・シネマの改修工事による閉鎖と、オークランドのマヌカウにある映画館の水害の影響が、業績に及んでいます。 最後に、スレッドボの2026年度の調整後EBITDAは、燃料費がドライブツーリズムに与える影響や6月の冬の天候状況によって変動するものの、2,200万豪ドルから2,300万豪ドルの範囲になると予想されています(提出書類による)。

Related Articles

Research

Morgan Stanley Downgrades AES to Equalweight From Overweight, Adjusts Price Target to $15 From $23

AES (AES) has an average rating of hold and mean price target of $15.12, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$AES
Australia

Compass Therapeutics Tovecimig Study Falls Short on Overall Survival Endpoint in Biliary Tract Cancer; Shares Fall Pre-Bell

Compass Therapeutics (CMPX) reported that its experimental drug tovecimig did not meet the overall survival secondary endpoint in a phase 2/3 study in patients with advanced biliary tract cancer, the company said Monday.Shares of the company fell more than 63% in recent pre-bell activity Monday.The company said that tovecimig plus paclitaxel did not show a statistically significant overall survival benefit versus chemotherapy alone, largely due to high crossover from the control arm and prolonged survival after switching to the drug.However, the study met other key endpoints, including statistically significant improvements in progression-free survival and overall response rate versus paclitaxel alone.Compass Therapeutics plans to meet with the US Food and Drug Administration to discuss the results ahead of a planned biologics license application submission, it added.Price: $1.91, Change: $-3.11, Percent Change: -63.35%

$CMPX
Sectors

Gold Eases Early Even as the Dollar Falls Ahead of This Week's U.S. Interest Rate Decision

Gold prices eased early on Monday, remaining rangebound even as the dollar fell ahead of the Wednesday interest-rate announcement from the Federal Reserve.Gold for June delivery was last seen down US$26.50 to US$4,714.40 per ounce, remaining within the US$200 range it has been stuck in since the start of the war on Iran, as high oil prices raise concerns over higher inflation and threaten to boost interest rates.The Federal Open Market Committee (FOMC) will make its latest interest-rate decision at the Wednesday afternoon end to its two-day meeting. The CME FedWatch Tool sees a 100% probability the group will leave rates unchanged."Gold remains stuck in neutral within a broad USD 200 range around USD 4,750, with most intraday price action dictated by energy prices and the ebb and flow of headlines from the White House and the Middle East. The FOMC is widely expected to leave rates unchanged on Wednesday," Saxo Bank noted.The dollar was lower early, with the ICE dollar index last seen down 0.28 points to 98.26. Treasury yields rose, with the yield on the two-year note up 1.0 basis points to 3.801%, while the 10-year note was paying 4.321%, up 1.3 points.

$GCM6$GLD